In patients with Chediak-Higashi syndrome undergoing allogeneic SCT, does adding etoposide to the conditioning regimen improve the outcome? [4]

Bone Marrow Transplantation

Volumn 40, Issue 6, 2007, Pages 603-

  Ayas, M ^a   Al Ghonaium, A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; STEROID; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CHEDIAK HIGASHI SYNDROME; CORRELATION ANALYSIS; DEATH; DONOR SELECTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; LETTER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEDIAK-HIGASHI SYNDROME; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548543248     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705774     Document Type: Letter

References (4)

1. Eapen M, Delaat CA, Baker KS, Cairo MS, Cowan MJ, Kurtzberg J et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant 2007; 39: 411-415.
2. Ouachée-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: A single center report of 48 patients. Pediatrics 2006; 117: E743-e750.
3. Bejaoui M, Veber F, Girault D, Gaud C, Blanche S, Griscelli C et al. The accelerated phase of Chediak-Higashi syndrome. Arch Fr Pediatr 1989; 46: 733-736.
4. Haddad E, Le Deist F, Blanche S, Benkerrou M, Rohrlich P, Vilmer E et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: Report of 10 cases. Blood 1995; 85: 3328-3333.